biote

Digital Health Expansion Will Elevate Preventative Care Despite Regulatory Hurdles

AnalystHighTarget

Not Invested

Consensus Narrative from 5 Analysts

Published

19 May 25

Updated

20 Aug 25

AnalystHighTarget's Fair Value

US$6.00

46.3% undervalued

20 Aug

US$3.22

-47.5%

6.6%

Author's Valuation

US$6.0

46.3% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$6.0

46.3% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

6.88%

Pharma revenue growth rate

0.58%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.78%

Calculation

US$6.99m

Earnings '28

35.00x

PE Ratio '28

US$244.66m

Market Cap '28

US$244.66m

Market Cap '28

33.50m

No. shares '28

US$7.30

Share Price '28

US$7.30 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$6.00

Fair Value '25